Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

MannKind Corporation (MNKD), Pfizer Inc. (PFE): Why Afrezza May Not Work

Page 1 of 2

MannKind Corporation (NASDAQ:MNKD) has been struggling to get its inhalable insulin product Afrezza on the market; the product was sent back to the labs by the Food and Drug Administration in 2011 for further trials. While the company recently achieved positive results in its phase 3 trials and is hoping to file an NDA soon, there’s a long story behind inhalable insulin that makes me uncomfortable with a stock completely focused on this product.

MannKind Corporation (NASDAQ:MNKD)

The long story — will it grow longer?
Inhalable insulin has a history almost as old as insulin itself. In the early 1920s, there were efforts made to create an inhaler because scientists thought people would be averse to pricking themselves in the arm once daily. That effort continued sporadically until 2006, when Pfizer Inc. (NYSE:PFE) got into the game after licensing the rights to a product that came to be known as Exubera.

Analysts averse to pricking themselves once daily predicted a huge future for the product. The product was, no doubt, innovative, requiring complex chemistry to create the airborne stream of insulin that would be properly absorbed in the blood capillaries in the correct amount. Billions of dollars were expected to come off the venture. Pfizer Inc. (NYSE:PFE) itself predicted $2 billion in annual sales.

Unfortunately, however, Exubera failed abysmally. In 2007, Pfizer Inc. (NYSE:PFE) had to recall the product from the market, and it said it would never develop it again. The company suffered a charge of $2.8 billion.

“We faced the combination of breaking through the barrier of conventional insulin therapy and the burden of the product on the medical practices, and this innovation was not accepted,” said Pfizer Inc. (NYSE:PFE) spokeswoman Vanessa Aristide in an email to BusinessWeek at the time.

How this affects Afrezza
This story is germane to Afrezza in two ways. One, because MannKind Corporation (NASDAQ:MNKD) has tried to solve some of the same problems that affected Nektar’s product. And two, because MannKind Corporation (NASDAQ:MNKD) has failed to realize the main problem vexing this budding market.

One of the problems that Afrezza has solved is size. Exubera was intimidating. Try flipping out a foot-size cylinder from your pocket during a dinner date and your date’s surprised face will tell you how discreet that is. Afrezza, on the other hand, is small and cool. It fits right into your palm, so you can use it without drawing attention in a public place. Or frightening your date at restaurants.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!